Teva QVAR Inhaler $35M Price-Fixing Class Action Settlement

Individuals and entities who purchased, paid for or provided reimbursement for QVAR or QVAR Redihaler inhalers in certain states between Jan. 1, 2015, and July 31, 2025, may be eligible to submit a claim for a payment from a class action settlement.

Teva Pharmaceutical Industries Ltd. and related entities agreed to pay $35 million to settle a class action lawsuit alleging they took steps to keep generic versions of QVAR off the market, resulting in higher prices for QVAR and QVAR Redihaler inhalers.

Who can file a claim for an asthma inhaler payout?

Class members must meet the following criteria:

• They purchased, paid for,or provided reimbursement for some or all of the purchase price of QVAR or QVAR Redihaler inhalers between Jan. 1, 2015, and July 31, 2025.
• The purchase or payment was for personal consumption or family members or, in the case of entities (third-party payers), for their members, insureds or beneficiaries.
• They made the purchase in one of the qualifying states or territories:
• Alaska
• Arkansas
• Arizona
• California
• Connecticut
• Delaware
• District of Columbia
• Florida
• Hawaii
• Illinois
• Indiana
• Iowa
• Kansas
• Maine
• Massachusetts
• Maryland
• Michigan
• Minnesota
• Mississippi
• Montana
• Nebraska
• Nevada
• New Hampshire
• New Jersey
• New Mexico
• New York
• North Carolina
• North Dakota
• Ohio
• Oklahoma
• Oregon
• Rhode Island
• South Dakota
• Tennessee
• Texas
• Utah
• Virginia
• Vermont
• Washington
• West Virginia
• Wisconsin
• Wyoming

How much are the price-fixing settlement payments?

• Pro rata cash payment: Eligible class members and entities can submit a claim to receive a cash payment from the net settlement fund. The settlement administrator will determine the payment amount by the total value of inhaler purchases claimed.

The settlement allocates 20.7% of the net settlement fund for individual consumer claims and 79.3% of the net settlement fund is allocated to third-party payor claims.

How to claim a class action rebate

Consumer class members can file a consumer claim online or print the consumer PDF claim form to complete and mail to the settlement administrator.

Third-party payor class members can file a TPP claim online or print the TPP PDF claim form to complete and mail to the settlement administrator.

Settlement administrator's mailing address: QVAR Antitrust Settlement, c/o A.B. Data Ltd., P.O. Box 173034, Milwaukee, WI 53217

The claim deadline is July 31, 2026.

Required proof and information for consumer claims

• All consumer claims require:
• The total number of QVAR and/or QVAR Redihaler products purchased during the qualifying period
• The total out-of-pocket the consumer amount paid for QVAR and QVAR Redihaler products during the qualifying period
• Supporting documentation, which may include the following:
• Pharmacy or insurer records showing QVAR or QVAR Redihaler purchases
• A note from a doctor or medical records describing prescriptions
• Explanation of benefits from a health plan or insurer
• Receipts, checkbook entries, credit card statements or other records showing purchases

Payout options

• Paper check mailed to the address provided

$35 million settlement fund breakdown

The $35,000,000 settlement fund will include:

• Notice and administration costs: To be determined
• Attorneys’ fees: Up to $11,550,000
• Litigation costs and expenses: Up to $890,000
• Service awards to class representatives: $25,000 each ($100,000 total)
• Payments to approved claimants: Remaining settlement funds

Important dates

• Deadline to opt out: June 15, 2026
• Deadline to file a claim: July 31, 2026
• Fairness hearing: Aug. 5, 2026

When is the QVAR antitrust settlement payout date?

The settlement administrator will issue payments to approved claimants after it completes claim processing and the court grants final approval of the settlement.

Why is there a class action settlement?

The class action lawsuit alleged Teva took actions to keep generic versions of QVAR off the market, including listing certain patents in the FDA’s orange book and discontinuing certain QVAR inhalers to maintain patent protection. The plaintiffs claimed these actions delayed generic competition and led to higher prices for QVAR and QVAR Redihaler.

Teva denies the allegations but agreed to settle to avoid the expense and risk of continued litigation and a possible trial. In addition to the settlement funds, Teva will also request removal of certain patents from the orange book, which could help bring generic versions to market sooner.

Sources

1. Class notice
2. Official settlement website
3. Consumer claim form